171 related articles for article (PubMed ID: 20402545)
1. Design and synthesis of highly selective Janus kinase 3 covalent inhibitors for the treatment of rheumatoid arthritis.
Yao H; Zhang J; Zheng Q; Zeng X; Huang H; Ling Z; Tang M; Chen Z; Wang W; He L
Arch Pharm (Weinheim); 2024 Jun; 357(6):e2300753. PubMed ID: 38442328
[TBL] [Abstract][Full Text] [Related]
2. Computer-Aided Drug Design of Novel Derivatives of 2-Amino-7,9-dihydro-8H-purin-8-one as Potent Pan-Janus JAK3 Inhibitors.
Faris A; Ibrahim IM; Al Kamaly O; Saleh A; Elhallaoui M
Molecules; 2023 Aug; 28(15):. PubMed ID: 37570884
[TBL] [Abstract][Full Text] [Related]
3. Integration of fingerprint-based similarity searching and kernel-based partial least squares analysis to predict inhibitory activity against CSK, HER2, JAK1, JAK2, and JAK3.
Deokar H; Deokar M; Buolamwini JK
Mol Divers; 2024 Apr; 28(2):497-507. PubMed ID: 36648693
[TBL] [Abstract][Full Text] [Related]
4.
Faris A; Cacciatore I; Ibrahim IM; Al Mughram MH; Hadni H; Tabti K; Elhallaoui M
J Biomol Struct Dyn; 2023 Oct; ():1-23. PubMed ID: 37861428
[TBL] [Abstract][Full Text] [Related]
5. Computational 3D Modeling-Based Identification of Inhibitors Targeting Cysteine Covalent Bond Catalysts for JAK3 and CYP3A4 Enzymes in the Treatment of Rheumatoid Arthritis.
Faris A; Alnajjar R; Guo J; Al Mughram MH; Aouidate A; Asmari M; Elhallaoui M
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202604
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore and Virtual Screening of JAK3 inhibitors.
Rajeswari M; Santhi N; Bhuvaneswari V
Bioinformation; 2014; 10(3):157-63. PubMed ID: 24748756
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in Pyrazole-based Protein Kinase Inhibitors as Emerging Therapeutic Targets.
Cetin A
Comb Chem High Throughput Screen; 2023 Nov; ():. PubMed ID: 37946345
[TBL] [Abstract][Full Text] [Related]
8. A hybrid energy-based and AI-based screening approach for the discovery of novel inhibitors of JAK3.
Wei J; Pan Y; Shen Z; Shen L; Xu L; Yu W; Huang W
Front Med (Lausanne); 2023; 10():1182227. PubMed ID: 37886358
[TBL] [Abstract][Full Text] [Related]
9. Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents.
Aboul-Soud MAM; Al-Sheikh YA; Ghneim HK; Supuran CT; Carta F
Expert Opin Ther Pat; 2024 May; ():1-10. PubMed ID: 38784980
[TBL] [Abstract][Full Text] [Related]
10. Inherent Fluorescence Demonstrates Immunotropic Properties for Novel Janus Kinase 3 Inhibitors.
Laux J; Martorelli M; Strass S; Schollmeyer D; Maier F; Burnet M; Laufer SA
ACS Pharmacol Transl Sci; 2023 Oct; 6(10):1433-1452. PubMed ID: 37854620
[TBL] [Abstract][Full Text] [Related]
11. It's ok to be outnumbered - sub-stoichiometric modulation of homomeric protein complexes.
Dimitrova YN; Gutierrez JA; Huard K
RSC Med Chem; 2023 Jan; 14(1):22-46. PubMed ID: 36760737
[TBL] [Abstract][Full Text] [Related]
12. Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds.
Sanachai K; Mahalapbutr P; Tabtimmai L; Seetaha S; Kittikool T; Yotphan S; Choowongkomon K; Rungrotmongkol T
ACS Omega; 2022 Sep; 7(37):33587-33598. PubMed ID: 36157733
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
14. JAK3 inhibition: what potential for the future?
Legendre C
Transplant Res; 2013 Nov; 2(Suppl 1):S6. PubMed ID: 24565406
[TBL] [Abstract][Full Text] [Related]
15. IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.
Choi J; Ziga ED; Ritchey J; Collins L; Prior JL; Cooper ML; Piwnica-Worms D; DiPersio JF
Blood; 2012 Nov; 120(19):4093-103. PubMed ID: 22972985
[TBL] [Abstract][Full Text] [Related]
16. Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells.
Cetkovic-Cvrlje M; Olson M; Ghate K
Cell Mol Immunol; 2012 Jul; 9(4):350-60. PubMed ID: 22728763
[TBL] [Abstract][Full Text] [Related]
17. Recent patents in the discovery of small molecule inhibitors of JAK3.
Wilson LJ
Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
19. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
